-

Half-Year Liquidity Contract Statement For MEDINCELL

PARIS--(BUSINESS WIRE)--Regulatory News:

Under the liquidity contract entered into between MEDINCELL (Paris:MEDCL) and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31st 2023:

- 26,969 shares
- € 304,190.38

- Number of executions on buy side on semester: 968
- Number of executions on sell side on semester: 1,058
- Traded volume on buy side on semester: 149,755 shares for € 946,754.61
- Traded volume on sell side on semester: 154,217 shares for € 994,397.98

As a reminder :

  • the following resources appeared on the last half year statement on 30 June 2023 on the liquidity account:

- 31,431 shares
- € 252,793.42

- Number of executions on buy side on semester: 1,690
- Number of executions on sell side on semester: 1,751
- Traded volume on buy side on semester: 220,419 shares for € 1,792,995.09
- Traded volume on sell side on semester: 227,949 shares for € 1,880,490.02

  • the following resources appeared on the liquidity account when the activity started:

- 0 shares
- € 200,000.00

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

 

 

Buy side

 

Sell side

 

Number of
executions

Number of
shares

Traded volume
in EUR

 

Number of
executions

Number of
shares

Traded volume
in EUR

Total

968

149,755

946,754.61

 

1,058

154,217

994,397.98

03/07/2023

25

4,519

28,379.32

 

3

500

3,295.00

04/07/2023

7

750

4,620.00

 

2

250

1,565.00

05/07/2023

7

1,231

7,570.65

 

-

-

-

06/07/2023

8

1,231

7,447.55

 

15

1,750

10,710.00

07/07/2023

2

500

3,045.00

 

15

2,000

12,260.00

10/07/2023

9

1,500

9,105.00

 

13

1,500

9,240.00

11/07/2023

1

250

1,535.00

 

17

2,750

17,297.50

12/07/2023

5

750

4,695.00

 

6

1,500

9,540.00

13/07/2023

12

1,251

7,906.32

 

5

813

5,219.46

14/07/2023

7

1,250

7,800.00

 

1

1

6.30

17/07/2023

14

1,941

11,762.46

 

4

750

4,567.50

18/07/2023

4

759

4,599.54

 

12

1,250

7,625.00

19/07/2023

-

-

-

 

17

2,500

15,575.00

20/07/2023

8

750

4,732.50

 

6

1,009

6,407.15

21/07/2023

2

500

3,150.00

 

2

500

3,180.00

24/07/2023

12

1,501

9,636.42

 

8

1,728

11,197.44

25/07/2023

14

2,756

17,335.24

 

20

3,001

18,996.33

26/07/2023

9

1,243

7,806.04

 

7

420

2,646.00

27/07/2023

4

677

4,271.87

 

7

1,079

6,873.23

28/07/2023

5

573

3,621.36

 

4

500

3,165.00

31/07/2023

1

250

1,575.00

 

4

750

4,770.00

01/08/2023

6

1,000

6,360.00

 

6

750

4,830.00

02/08/2023

13

2,250

13,860.00

 

18

1,751

10,943.75

03/08/2023

6

1,250

7,975.00

 

12

2,499

16,518.39

04/08/2023

-

-

-

 

39

6,000

41,640.00

07/08/2023

12

2,250

15,435.00

 

21

2,250

15,840.00

08/08/2023

10

2,500

16,700.00

 

5

1,250

8,437.50

09/08/2023

8

1,500

9,930.00

 

1

250

1,700.00

10/08/2023

5

500

3,315.00

 

3

500

3,365.00

11/08/2023

4

750

5,032.50

 

2

500

3,415.00

14/08/2023

16

1,750

11,480.00

 

1

1

6.70

15/08/2023

3

500

3,250.00

 

6

500

3,290.00

16/08/2023

6

1,307

8,586.99

 

10

1,249

8,280.87

17/08/2023

9

1,693

10,818.27

 

-

-

-

18/08/2023

4

1,000

6,240.00

 

1

115

724.50

21/08/2023

4

1,000

6,310.00

 

13

1,635

10,431.30

22/08/2023

2

250

1,625.00

 

13

1,500

9,825.00

23/08/2023

6

1,011

6,632.16

 

10

1,500

9,960.00

24/08/2023

7

548

3,666.12

 

7

1,520

10,229.60

25/08/2023

7

717

4,739.37

 

1

1

6.70

28/08/2023

2

291

1,917.69

 

3

500

3,330.00

29/08/2023

1

250

1,660.00

 

8

1,284

8,744.04

30/08/2023

13

1,764

11,836.44

 

3

251

1,731.90

31/08/2023

2

500

3,350.00

 

8

750

5,122.50

01/09/2023

2

251

1,691.74

 

6

751

5,114.31

04/09/2023

2

250

1,700.00

 

3

499

3,433.12

05/09/2023

2

500

3,385.00

 

3

256

1,766.40

06/09/2023

3

501

3,366.72

 

10

940

6,476.60

07/09/2023

4

500

3,435.00

 

5

750

5,265.00

08/09/2023

-

-

-

 

14

2,250

16,312.50

11/09/2023

12

1,750

12,565.00

 

4

750

5,512.50

12/09/2023

9

1,288

9,170.56

 

5

1,250

9,025.00

13/09/2023

8

1,212

8,532.48

 

-

-

-

14/09/2023

9

750

5,220.00

 

1

250

1,750.00

15/09/2023

5

1,000

6,870.00

 

1

50

350.00

18/09/2023

14

1,683

11,191.95

 

-

-

-

19/09/2023

23

2,001

12,886.44

 

13

1,343

8,675.78

20/09/2023

3

501

3,231.45

 

26

1,409

9,172.59

21/09/2023

18

2,250

14,355.00

 

2

250

1,640.00

22/09/2023

3

750

4,612.50

 

3

500

3,140.00

25/09/2023

6

1,250

7,675.00

 

7

1,250

7,725.00

26/09/2023

4

251

1,556.20

 

13

2,000

12,660.00

27/09/2023

9

1,271

8,032.72

 

24

3,580

23,520.60

28/09/2023

21

2,430

15,430.50

 

9

1,750

11,252.50

29/09/2023

10

1,499

9,623.58

 

3

501

3,271.53

02/10/2023

12

1,500

9,390.00

 

2

14

90.44

03/10/2023

12

2,250

13,792.50

 

9

1,800

11,322.00

04/10/2023

6

1,000

6,060.00

 

8

1,000

6,090.00

05/10/2023

2

500

3,050.00

 

11

1,000

6,140.00

06/10/2023

2

500

3,070.00

 

3

500

3,085.00

09/10/2023

9

1,000

6,130.00

 

2

250

1,540.00

10/10/2023

2

500

3,110.00

 

7

1,500

9,375.00

11/10/2023

8

1,573

9,846.98

 

13

1,966

12,425.12

12/10/2023

6

1,251

7,931.34

 

10

1,412

8,994.44

13/10/2023

3

278

1,748.62

 

3

72

457.92

16/10/2023

-

-

-

 

8

779

4,993.39

17/10/2023

8

1,248

7,862.40

 

8

820

5,207.00

18/10/2023

11

1,219

7,679.70

 

4

589

3,716.59

19/10/2023

8

774

4,876.20

 

10

932

5,927.52

20/10/2023

14

2,008

12,329.12

 

3

264

1,636.80

23/10/2023

8

1,001

6,066.06

 

7

987

6,000.96

24/10/2023

5

502

3,057.18

 

2

250

1,525.00

25/10/2023

34

4,444

25,952.96

 

4

1,000

5,970.00

26/10/2023

11

1,341

7,603.47

 

6

750

4,290.00

27/10/2023

4

1,000

5,750.00

 

11

1,250

7,275.00

30/10/2023

15

2,417

13,897.75

 

9

1,250

7,400.00

31/10/2023

9

1,455

8,162.55

 

4

560

3,169.60

01/11/2023

9

1,468

7,941.88

 

3

501

2,745.48

02/11/2023

-

-

-

 

14

1,715

9,844.10

03/11/2023

3

295

1,690.35

 

9

1,001

5,885.88

06/11/2023

13

2,206

12,574.20

 

3

510

2,912.10

07/11/2023

9

1,251

7,168.23

 

14

2,241

13,042.62

08/11/2023

5

1,250

7,250.00

 

18

3,500

20,685.00

09/11/2023

4

500

3,010.00

 

8

1,250

7,625.00

10/11/2023

9

1,750

10,517.50

 

5

1,000

6,060.00

13/11/2023

7

1,100

6,523.00

 

12

1,500

8,970.00

14/11/2023

-

-

-

 

21

2,985

18,178.65

15/11/2023

5

677

4,102.62

 

5

394

2,395.52

16/11/2023

6

823

4,962.69

 

4

501

3,036.06

17/11/2023

2

250

1,500.00

 

1

172

1,049.20

20/11/2023

4

750

4,537.50

 

14

2,016

12,257.28

21/11/2023

3

750

4,672.50

 

12

2,149

13,517.21

22/11/2023

13

2,750

16,912.50

 

6

1,251

7,743.69

23/11/2023

13

1,750

10,622.50

 

2

500

3,050.00

24/11/2023

11

1,250

7,550.00

 

9

1,749

10,738.86

27/11/2023

2

372

2,298.96

 

8

1,750

10,902.50

28/11/2023

5

628

3,868.48

 

6

750

4,650.00

29/11/2023

13

1,750

10,780.00

 

3

270

1,676.70

30/11/2023

4

750

4,597.50

 

4

730

4,518.70

01/12/2023

7

1,250

7,675.00

 

7

1,500

9,255.00

04/12/2023

-

-

-

 

4

750

4,657.50

05/12/2023

6

750

4,642.50

 

5

750

4,717.50

06/12/2023

24

2,449

14,865.43

 

3

500

3,045.00

07/12/2023

12

1,501

8,930.95

 

3

562

3,372.00

08/12/2023

-

-

-

 

25

2,938

18,009.94

11/12/2023

-

-

-

 

30

4,750

31,112.50

12/12/2023

27

5,500

36,685.00

 

16

2,866

19,660.76

13/12/2023

13

2,500

16,275.00

 

9

1,500

9,945.00

14/12/2023

3

750

5,085.00

 

16

1,756

11,993.48

15/12/2023

9

1,000

6,790.00

 

13

1,378

9,439.30

18/12/2023

11

2,250

15,322.50

 

12

2,115

14,593.50

19/12/2023

6

1,000

6,920.00

 

12

2,135

14,923.65

20/12/2023

31

6,250

41,750.00

 

3

437

3,019.67

21/12/2023

12

1,750

11,620.00

 

8

1,313

8,797.10

22/12/2023

6

1,323

8,705.34

 

4

501

3,336.66

27/12/2023

1

250

1,685.00

 

12

2,176

14,688.00

28/12/2023

1

250

1,750.00

 

19

3,724

26,068.00

29/12/2023

1

250

1,760.00

 

21

3,750

27,075.00

MEDINCELL
Public limited company with a capital of € 248 154.63
Registered office: 3 rue des Frères Lumière 34830 Jacou
444 606 750 R.C.S. on the Montpellier Trade and Companies Register

Contacts

MEDINCELL

MEDINCELL

BOURSE:MEDCL

Release Versions

Contacts

MEDINCELL

More News From MEDINCELL

Medincell to Participate in Leerink and Jefferies Miami Investor Conferences, March 8 – 11, 2026

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced its participation to the 2026 Leerink Global Healthcare Conference and Jefferies Biotech on the Beach Summit in Miami, Florida, March 8 – 11, 2026. Meetings with Christophe Douat, Chief Executive Officer, and Dr Grace Kim, Chief Strategy Officer, U.S. Finance, may be arranged v...

Medincell to Present at the TD Cowen 46th Annual Healthcare Conference in Boston, March 2-4, 2026

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments (the "Company"), today announced its participation at the TD Cowen 46th Annual Healthcare Conference, which will take place March 2-4, 2026 in Boston. The Company will present on Tuesday, March 3, 2026, at 1:50pm ET. Investor meetings with Dr Grace Kim, Chief Strategy Officer, U.S. Finance, may...

Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS--(BUSINESS WIRE)--Regulatory News: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for olanzapine extended-release injectable suspension (TEV-'749) for the treatment of schizophrenia in adults. TEV-'749 is designed to improve real-world treatment adherence and...
Back to Newsroom